Get the Stockscreener App
164.20
2.51%
4.02
After Hours:
164.20
Belite Bio Inc Adr stock is traded at $164.20, with a volume of 535.96K.
It is up +2.51% in the last 24 hours and up +9.47% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$160.18
Open:
$162.41
24h Volume:
535.96K
Relative Volume:
2.94
Market Cap:
$6.16B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-139.84
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
+2.65%
1M Performance:
+9.47%
6M Performance:
+180.06%
1Y Performance:
+179.44%
1-Day Range:
$158.00
$165.25
1-Week Range:
$153.56
$165.25
52-Week Range:
$49.00
$169.75
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
164.20 | 6.01B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com
Belite Bio (NASDAQ:BLTE) Lowered to Sell Rating by Wall Street Zen - Defense World
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target By Investing.com - Investing.com Nigeria
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Behavioral Patterns of BLTE and Institutional Flows - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Up 5.5%Should You Buy? - MarketBeat
Belite Bio stock hits all-time high at 163.25 USD - Investing.com
Belite Bio stock hits all-time high at 163.25 USD By Investing.com - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Down 45.2% in December - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Sets New 1-Year HighHere's Why - MarketBeat
Can Belite Bio Inc (Common Stock) (D01) stock attract analyst upgradesMarket Movers & Expert Approved Trade Ideas - Улправда
Belite Bio, IncDepositary Receipt (BLTE) Price Target Increased by 21.98% to 116.02 - MSN
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Here’s What Happened - Defense World
Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease - MSN
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week HighShould You Buy? - MarketBeat
Belite Bio stock hits all-time high at 160.74 USD - Investing.com
Belite Bio stock hits all-time high at 160.74 USD By Investing.com - Investing.com Canada
Price-Driven Insight from (BLTE) for Rule-Based Strategy - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Clene (CLNN) and Costco (COST) - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho - MarketBeat
FY2025 EPS Estimates for Belite Bio Lowered by HC Wainwright - MarketBeat
Belite Bio (NASDAQ:BLTE) Raised to “Outperform” at Mizuho - Defense World
Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering - MSN
Belite Bio (NASDAQ:BLTE) Shares Gap UpWhat's Next? - MarketBeat
Belite Bio stock price target raised to $187 from $132 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio stock price target raised to $187 from $132 at Benchmark - Investing.com Nigeria
Is Belite Bio’s Surge Justified by DCF Upside and Price to Book Signals? - Sahm
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs - The Globe and Mail
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development - TipRanks
Does Belite Bio Inc ADR (BLTE) offer a good opportunity for investors? - Setenews
Mizuho upgrades Belite Bio stock to Outperform on positive trial data By Investing.com - Investing.com South Africa
Mizuho upgrades Belite Bio stock to Outperform on positive trial data - Investing.com Australia
Why Belite Bio’s Stock is Making Waves - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Belite Bio prices public offering of ADSs at $154 each - Investing.com
Belite Bio prices public offering of ADSs at $154 each By Investing.com - Investing.com India
Belite Bio (NASDAQ: BLTE) prices $350M ADS offer to back commercialization, pipeline - Stock Titan
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):